

To whom it may concern:

Company Name Corporate Representative	TOHO HOLDINGS CO., LTD. Atsushi Udoh, President and Representative Director (First Section of Tokyo Stock Exchange Securities Code:8129)
Contact:	Makoto Kawamura, Director and General Manager, Corporate Management Division and Corporate Planning and Investor Relations Department (TEL: 81-3-6838-2803)

### Notice Regarding Full-Year Earnings Forecasts for Fiscal Year Ended March 2021 and Recording of Extraordinary Loss

TOHO HOLDINGS CO., LTD. (the “Company”) is pleased to announce its full-year earnings forecasts for the fiscal year ended March 2021, which were uncertain when the “Summary of Consolidated Financial Results for the Third Quarter of Fiscal Year Ending March 31, 2021” was released on February 9, 2021, and the posting of an extraordinary loss as given below.

#### 1. Consolidated Projected Results of Operations during Fiscal Year Ended March 2021

(From April 1, 2020 to March 31, 2021)

	Net Sales	Operating Income	Ordinary Income	Profit Attributable to Owners of Parent	Net Income per Share
	Million yen	Million yen	Million yen	Million yen	Yen
Previous forecast (A)	—	—	—	—	—
Revised forecast (B)	1,210,000	4,200	10,200	4,900	69.49
Increase/Decrease (B-A)	—	—	—	—	
Change (%)	—	—	—	—	
(Reference) Result of FY ended March 2020	1,263,708	17,590	23,732	16,230	233.34

#### 2. Reason for the Earnings Forecasts

The forecasts of consolidated earnings for the fiscal year ended March 2021 were uncertain because of difficulty in rationally calculating the impact of the spread of the new novel coronavirus infection (COVID-19). However, the Company forecasts that both net sales and income will be lower than those of the previous year due to the tendency to limit clinic visits by patients, who were alerted to the risks of COVID-19 and price competition among wholesalers, in addition to the adverse effects from ongoing measures to curtail medical expenses such as NHI drug price revisions in April 2020 and promoting the use of generic drugs.

In addition, TOHO PHARMACEUTICAL CO., LTD., our consolidated subsidiary, was criminally charged by the Japan Fair Trade Commission on December 9, 2020, on suspicion of violating the Antimonopoly Act when bidding to supply ethical pharmaceuticals to Japan Community Health care Organization (JCHO) and was subsequently indicted by the Tokyo District Public Prosecutors Office. The Company estimates that related losses could total 4,213 million yen and plans to record them as an extraordinary loss. This is included in the above forecasts.

(Note) The above earnings forecasts have been prepared based on information available as of the announcement date of this document. Actual performance may differ from the forecasted figures for various reasons.